血清Flt3L和Gas6水平对非霍奇金淋巴瘤患者利妥昔单抗化疗后肺部感染预测价值分析  

Predictive value of serum Flt3L and Gas6 levels for pulmonary infection in patients with non-Hodgkin’s lymphoma after rituximab chemotherapy

作　　者：陈瑜 陶石[1] 胡敏[1] 符才波 CHEN Yu;TAO Shi;HU Min;FU Caibo(Hematology Department,the First Affiliated Hospital of Hainan Medical University,Haikou,Hainan,China,570100)

机构地区：[1]海南医学院第一附属医院血液内科,海南海口570100

出　　处：《分子诊断与治疗杂志》2022年第4期652-655,659,共5页Journal of Molecular Diagnostics and Therapy

基　　金：吴阶平医学基金会临床科研专项资助基金(320.3750.18389)。

摘　　要：目的探讨血清FMS样酪氨酸激酶3配体(Flt3L)和生长停滞特异性蛋白6(Gas6)水平对非霍奇金淋巴瘤患者利妥昔单抗化疗后肺部感染的诊断价值。方法选取2019年7月至2021年7月在海南医学院第一附属医院血液内科收治的116例非霍奇金淋巴瘤患者作为研究对象,根据利妥昔单抗化疗后是否发生肺部感染分为肺部感染组48例、非肺部感染组29例以及未感染组39例。对比三组患者一般资料情况以及实验室指标水平,Logistic回归分析化疗后发生肺部感染的危险因素,ROC曲线分析其危险因素对患者化疗后发生肺部感染的预测价值。结果三组肺部疾病史、血清Flt3L、Gas6水平比较:肺感染组>非肺部感染组>未感染组,差异有统计学意义(P<0.05),Logistic回归分析显示,血清Flt3L、Gas6水平升高是患者化疗后发生肺部感染的独立危险因素(P<0.05),ROC曲线图结果显示,血清Flt3L、Gas6水平联合预测非霍奇金淋巴瘤患者利妥昔单抗化疗后肺部感染的曲线下面积(AUC)为0.879,高于单一检测(P<0.05)。结论非霍奇金淋巴瘤患者血清Flt3L和Gas6水平升高是利妥昔单抗化疗后发生肺部感染的独立危险因素,早期联合检测血清Flt3L和Gas6水平有利于预测患者化疗后感染情况和病情判断。Objective To investigate the value of serum FMS⁃like tyrosine kinase 3 ligand(Flt3L)and growth arrest⁃specific protein 6(Gas6)levels in the diagnosis of pulmonary infection in patients with non⁃Hodgkin's lymphoma after rituximab chemotherapy.Methods 116 patients with non⁃Hodgkin's lymphoma who were admitted to the Department of Hematology,The First Affiliated Hospital of Hainan Medical University from July 2019 to July 2021 were selected as the research subjects.According to whether pulmonary infection occurred after rituximab chemotherapy,they were divided into 48 cases of pulmonary infection group,29 cases of non⁃pulmonary infection group and 39 cases of non⁃infection group.The general data and laboratory index levels of the three groups of patients were compared.Logistic regression was used to analyze the risk factors of pulmonary infection after chemotherapy,and the ROC curve was used to analyze the predictive value of the risk factors for the occurrence of pulmonary infection in patients after chemotherapy.Results Comparison of the history of lung disease,serum Flt3L and Gas6 levels among the three groups:lung infection group>non⁃pulmonary infection group>lung infection group,the difference was statistically significant(P<0.05).Logistic regression analysis showed that elevated serum Flt3L and Gas6 levels were independent risk factors for pulmonary infection after chemotherapy(P<0.05).The results of ROC curve analysis showed that the AUG values of serum Flt3L,Gas6 and combined detection for pulmonary infection were 0.848,0.758 and 0.892 respectively(P<0.05).Conclusion Elevated serum Flt3L and Gas6 levels in patients with non⁃Hodgkin lymphoma are independent risk factors for pulmonary infection after rituximab chemotherapy.Early combined detection of serum Flt3L and Gas6 levels is helpful for predicting the infection status and disease judgment of patients after chemotherapy.

关 键 词：血清FMS样酪氨酸激酶3配体 生长停滞特异性蛋白6 非霍奇金淋巴瘤 肺部感染 

分 类 号：R733.1[医药卫生—肿瘤]